KYTX

Kyverna Therapeutics
$7.92
+$0.51 (+6.88%)Jul 27, 2026
3.4FairMoatMint rating

MoatMint rates Kyverna Therapeutics (KYTX) 3.4 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.3 out of 10.

Key metrics

The numbers that frame KYTX today
Market cap
$481.50M
P/E (TTM)
-3.1
EV / FCF
-3.2
ROIC
-95.2%
Div yield
0%
Debt / equity
0.2
52wk Low
$2.80
52wk High
$13.67

KYTX stock rating

How KYTX scores on quality, value, growth, momentum and financial health
3.4out of 10
Fair overallHealthy business, expensive priceTop 66% of ~5,000 US stocks
QualityPoor1.3/10
GrowthGreat9.2/10
MomentumGood7.8/10
ValuePoor1.2/10
Financial HealthFair2.5/10

Growth

Revenue and earnings trend for KYTX
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about KYTX
Is Kyverna Therapeutics a good buy?
Hold. Kyverna Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Kyverna Therapeutics is selling at a very high price.
What is the market capitalization of KYTX?
Kyverna Therapeutics's market capitalization is $481.50M.
What is the P/E ratio for KYTX stock?
Kyverna Therapeutics's current P/E ratio is -3.1.
What is the 52-week high for KYTX stock?
The 52-week high for Kyverna Therapeutics is $13.67. The current close of $7.92 is 42.1% below that high.
What is the 52-week low for KYTX stock?
The 52-week low for Kyverna Therapeutics is $2.80. The current close of $7.92 is 182.9% above that low.
Does KYTX stock pay dividends?
Kyverna Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for KYTX?
Kyverna Therapeutics's Debt / Equity ratio is 0.17.